Lyrica is a Schedule V controlled substance
Executive Summary
Pfizer plans to launch Lyrica (pregabalin) in the fall following DEA's July 28 final rule classifying the drug as a Schedule V controlled substance. Launch of the gabapentin follow-on has been delayed by the scheduling process. FDA cleared pregabalin in December for neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia; Lyrica added an indication for partial onset seizures in June (1"The Pink Sheet" June 20, 2005, In Brief)...
You may also be interested in...
Lyrica adds third indication
Pfizer's Lyrica (pregabalin) clears FDA June 10 for treatment of partial onset seizures. The Neurontin follow-on was approved for diabetic peripheral neuropathy and postherpetic neuralgia in December 2004 (1"The Pink Sheet" Jan. 10, 2005, p. 5). Lyrica's launch is awaiting final Drug Enforcement Agency scheduling. Pfizer says pregabalin will be available in pharmacies in the fall...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.